To further assess the humoral immune responses and simultaneously evaluate efficacy of vIND-ZIKV, we utilized a ZIKV challenge model22 where C57BL/6 mice are made transiently susceptible to ZIKV infection by administering an anti-IFNAR1 monoclonal antibody23 1 day prior to challenge. This evidence concerns the gene IFNAR1 and Zika virus infectious disease.